Binghampton, NY (Hepatitis C)
Trinity Memorial Church
44 Main Street
Binghamton, New York
Meets: Every Other Tuesday at 6:00PM
Contact Steve Hanankovic for more information.
Phone: 607-798-1706
Email: Binghampton, NY (Hepatitis C)
Brooklyn - Hepatitis C Support Group
New York Methodist Hospital - (Directions)
Carrington Pavilion Entrance, 506 Sixth Street between 7th and 8th Avenues (See Details Below)
Brooklyn, NY
Meets: Meets First Tuesday of each Month 6:00 PM to 7:30 PM
Getting There: Executive Dining (next to Hospital Cafeteria) Carrington Pavilion entrance 506 Sixth Street between 7th and 8th Avenues Park Slope, Brooklyn; Public Transportation: F Train to Seventh Avenue. B67 (Seventh Ave.), B63 (Fifth Ave.), B75 (Smith St.), and B69 (Vanderbilt Ave.)
Refreshments will be served.
Contact Betty Vega for more information.
Phone: (718) 780-5367
Email: Brooklyn - Hepatitis C Support Group
Brooklyn - NY (Hepatitis-C)
Kings Pharmacy - (Directions)
357 Flatbush Avenue
Brooklyn, NY
Meets: Meets first Wednesday of each Month, 5:00-7:00pm
- Do you have questions about your medications?
- Do you want to improve your quality of life?
- Do you want to hear & share ideas with other people in your condition?
Directions:B/Q train to 7th Avenue or 2/3 train to Grand Army Plaza or B41 bus to Flatbush and 7th Avenue
Next Meeting: April 2nd.
Refreshments will be served!!!
**Free and open to the public.
Contact Sweta Chawla for more information.
Phone: 718-230-3535 ext 23
Kingston, NY (Hepatitis C)
Benedictine Hospital - (Directions)
Mary's Avenue
Kingston, NY 12401
Meets: Meets every 2nd & 4th Thursday Monthly, 7:00 PM
*Not Sponsored by ALF
Contact Harvey Bostic for more information.
Phone: (845) 331-6266
Long Island (Hepatitis C)
North Shore University Hospital at Plainview - (Directions)
888 Old Country Road
Plainview, NY
Meets: Meets first Monday of each month, 7pm - 9pm
Meeting Details: Meeting is in basement in Lecture Room A. Schedule changes may occur to accomodate certain holidays.
Contact Gina Pollichino, RN (American Liver Foundation) for more information.
Phone: (631) 754-4795
Email: Long Island (Hepatitis C)
Long Island (Hepatitis C)
Huntington Hospital - (Directions)
270 Park Avenue
Huntington, NY
Meets: Meets second Tuesday of each month, 7pm-9pm
Meeting Details: Meeting is in Trailer #1 (wooden trailers in front parking lot). Schedule changes may occur to accommodate certain holidays.
Contact Gina Pollichino, RN (American Liver Foundation) for more information.
Phone: (631) 754-4795
Email: Long Island (Hepatitis C)
Long Island (PBC)
*Not sponsored by ALF
Contact Marilyn Klainberg for more information.
Contact Marilyn Klainberg for more information.
Phone: 516-877-4568
Newark - NJ (Hepatitis C and or HIV)
Saint Michael's Medical College
111 Central Avenue
Newark, NJ 7102
Meets: Last Wenesday of the Month at 12 Noon
Contact Nancy Scangarello for more information.
Phone: 973-877-5645
NJ - Caregiver Support Group
Christian Health Care Center - (Directions)
301 Sicomac Road
Wyckoff, NJ 07481
Meets: Second Tueday of the month, 12:00-1:00pm
Open to all caregivers.
Contact Barbara Suskin for more information.
Phone: 201-848-5830
NYC - Manhattan (HCV Support Group)
Lower East Side Harm Reduction Center
25 Allen Street
New York, NY 10002
Meets: Fridays 12:00 - 1:30PM
Contact Monique for more information.
Phone: 212-226-6333 ext 119
Email: NYC - Manhattan (HCV Support Group)
NYC - Manhattan (Hepatitis C)
Center for the Study of Hepatitis C
1305 York Ave at 70th and York, 2nd Floor Patient Resource Center
New York, NY
Meets: First Wednesday of the month; 4:00-5:00pm
Contact Mary Olson for more information.
Phone: 646-962-4742
NYC - Manhattan (Hepatitis C)
Mount Sinai Medical Center, Guggenheim Pavillion - (Directions)
100th Street and Madison
2nd Floor, Room 2C
New York, NY
Meets: Third Wednesday of each month; 6- 7:30 p.m.
Contact Viktoriya Khaitova for more information.
Phone: 212-241-5736
NYC - Manhattan (Hepatitis C)
Harlem Hospital Center, The Ron Brown Clinic, 3rd Floor, Conference Room 3071 - (Directions)
506 Lenox Avenue
New York, NY 10037
Meets: meets the second Friday monthly; 10-11am
Phone: 212-939-1000
NYC - Manhattan (Hepatitis C)
Weill Medical College of Cornell University/New York Presbyterian Hospital - (Directions)
450 East 69th Street and York Ave
New York, NY
Meets: meets first Wednesday monthly; 6-7pm
Contact Mary Ahern, NP for more information.
Phone: 646-962-4040
NYC - Manhattan (Hepatitis C)
St. Vincent's Hospital, Coleman Building Room 1249 - (Directions)
170 West 12th Street (at 7th Avenue, SE corner) in Coleman 1249
New York, NY
Meets: Tuesday, April 15th, 2008 6pm (Third Tuesday Monthly; 6-8pm)
This meeting is open to anyone impacted by or interested in Hepatitis C. That includes healthcare professionals, patients, care providers, family etc.
We meet the third Tuesday of each month. Our next meeting will be March 18th at 6 PM.
It's been established that a strong social support helps people dealing with a difficult condition. Come join us to add to your support system. We try to offer education, information, a shoulder with a network and lest I forget---refreshments!
The doctors at St. Vincent's have made a commitment to our support group to try to have one of their staff attend our meetings. This is an effort to offer us medical information and guidance and in return they develop a better understanding of how Hepatitis C impacts us as patients.
This month we will be joined by Louis Alberto Colon who is a specialist in HCV. He represents Roche Pharmaceuticals.
Refreshments will be provided courtesy of Roche Pharmaceuticals.
Contact Lillian de Mauro, lilliandem@gmail.com for more information.
Phone: 718-545-5234
NYC - Manhattan (HVC Support Group)
Positive Health Project
301 West 37th Street
New York, NY 10018
Meets: Every Friday; 1:00-2:00pm
Contact Kevin Norsleet for more information.
Phone: 212-465-8304
NYC - Manhattan (L.O.L.A. Support Group)
New York Blood Center - (Directions)
310 East 67th Street
New York, NY
Meets: Third Wednesday monthly; 6pm
Phone: 718-892-8697
NYC - Midtown Manhattan (NYU Hepatitis C Support Group)
New York University Medical Center - (Directions)
560 1st Ave. (between 30th and 31st) , Main entrance of NYU Medical Center
Smilo Conference Room, Room A
New York, NY
Meets: Wednesday April 30th, 2008 6:15 PM
This month's meeting will be conducted by: Leena K. Hong, RPC-C & Ronni Marks.
"An overview of Hepatitis C"
Refreshments will be provided by:
Three Rivers Pharmaceuticals
**This meeting is free of charge and is open to patients, friends and familites from all other offices and hospitals.
Contact Leena K. Hong for more information.
Phone: 212-889-5544
NYC - Post Transplant Support Group
New York Presbyterian Hospital - Milstein Hospital Building - (Directions)
177 Fort Washington Avenue
7 Hudson South - Reemtsma Conference Room 213
New York, NY
Meets: First and Third Thursday of every month, 10:00-11:30AM
The Post-Transplant Support Group meets twice a month to share experiences, ideas and mutual support.
Contact Aimee Muth for more information.
Phone: 212-305-1884
NYC - Transplant Caregivers Forum
New York Presbyterian Hospital - Milstein Hospital Building - (Directions)
177 Fort Washington Avenue
7 Hudson South - Reemtsma Conference Room 213
New York, NY
Meets: Secong and Fourth Thursday of every month, 4:00-6:00PM
As transplantation is a very stressful time for caregivers as well as patients, the Caregivers Forum meets twice a month, offering participants the opportunity to receive education and support from other transplant caregivers to assist in coping with the transplant process.
Contact Kimberly Morse for more information.
Phone: 212-305-3081
NYC - Transplant Support Group
The Recanati/Miller Transplantation Institute at Mount Sinai Hospital - (Directions)
One Gustave L. Levy Place
New York, NY 10029
Meets: Thursdays 1pm
This support group is open to all patients and patient's family members who are pre or post liver and/or kidney transplantation. Entrance on 1468 Madison Ave.; (100th St. and Madison Ave.); Guggenheim Pavillion; Floor: 9 Center, Patient Lounge
Phone: (212) 241-7944
Staten Island - NY (HIV - HCV Coinfection Support Group)
Community Health Action of Staten Island HIV - HCV Coinfection Support Group - (Directions)
56 Bay Street, 6th Floor Conference Room
Staten Island, NY 10301
Meets: Fourth Thursday of Every Month, 1:00-2:00PM
Meeting is facilitated by Joe Grossman from the harm Reduction program @ Staten Island University Hospital.
Next Meeting: Thursday March 27th.
Contact Barbara Sullivan for more information.
Phone: 718-808-1314
Email: Staten Island - NY (HIV - HCV Coinfection Support Group)
Transplant Support Organization Serving the NY of Westchester, Bronx, Putnam and Dutchess
Congregation Sons of Israel - (Directions)
1666 Pleasantville Road
Briarcliff Manor, NY
Meets: Every Third Wednesday of each month, 7:00-9:00PM
Contact Robert DiStasio for more information.
Phone: 914-946-0462
Web: www.transplantsupport.org
Email: Transplant Support Organization Serving the NY of Westchester, Bronx, Putnam and Dutchess
TRIO - Transplant Recipients International Organization
Individuals who have undergone transplant surgery provide support for other transplant candidates, recipients, their families and donor family members.
TRIO Long Island
Michael Sosna, President
PO Box 81, Garden City, NY 11530
516-942-4940
TRIO Manhattan
Larraine DePasquale, President
PO Box 122, Throggs Neck Station, Bronx, NY 10461
718-597-5619
Westchester County (Hepatitis C)
Westchester Medical Center
Meets: every other Wednesday; 6-8pm
Contact Mimi Greenman for more information.
Phone: 914-493-7641
Wilson Disease Support Group
152 Cheese Spring Road
Wilton, CT 06897
Meets: Depending on doctor's schedule
Contact Lenore Sillery for more information.
Phone: 203-961-9993
Ascites: Percutaenous Drainage
New York Medical Center
Valhalla, NY 10595
Treatment of Intractable Debilitating Ascites by Percutaneous Drainage into the Urinary Bladder.
INCLUSION CRITERIA: The presence of intractable, debilitating ascites. Age 19-80.
PRINCIPAL INVESTIGATOR: Edward Lebovics, MD, David Wolf, MD, Grigory Rozenblit, MD
Contact Jody Hirsch, RPA-C for more information.
Phone: 914-594-3448
Drug-Induced Liver Injury: DILIN
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME:Idiosyncratic Liver Injur Associated with Drugs; A Retrospective Study [The Drug-Induced Liver Injury Network (DILIN)]
SUMMARY:Liver injury is the most common reason why drugs are not approved by the U.S. Food and Drug Administration in the first place or are later removed from the market. Relatively few people experience liver problems, but it is unclear why this even happens at all. The University of Connecticut Health Center is currently conducting a research study to explore these issues in more detail so that safer and more effective drugs can be developed in the future. For this study we are focusing on the following drugs: isoniazid, phenytoin, clavulanic acis/amoxicillin (Augmentin), and valproic acid.
Who is eligible?
SPONSOR:The National Institutes of Health, through the UCHC General Clinical Research Center.
Phone: 860-679-8063
Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronic Hepatitis B
Yale University School of Medicine
Who is Eligible: Persons with HBV and cirrhosis
Trial Description: Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected with Hepatitis B Virus and Evidence of Hepatic Decompensation
Doctor: Joseph K. Lim, M.D.
Contact Hong Chau, MPH for more information.
Phone: (203) 737-6063
HBV - Clevudine vs. Adefovir in Patients with Chronic Hepatitis B who have Never Been Treated
Phillips Ambulatory Care Center - (Directions)
10 Union Square East
New York, NY 10003
Principal Investigator: Albert Min, MD
Time frame of study: September 2007 – December 2012
Time frame of participation: 96 weeks
Number of participants needed: Open
Summary:
The Division of Digestive Diseases is conducting a pivotal clinical study of an investigational medicine for patients 18 and older with chronic hepatitis B who have never been treated. The purpose of the trial is to evaluate the effectiveness and safety of Clevudine, the investigational medicine, as compared to adefovir.
Criteria for Participation:
Patients must be:
• At least 18 years of age
• Treatment naïve
• Willing to have a liver biopsy if they have not had one within 6 months of starting the study and at Week 48 of the study
• Infected with chronic hepatitis B and have abnormal liver blood tests
• Not pregnant or breast-feeding
• Not have a history or presence of other liver diseases
• Able to meet other criteria that will be discussed at a screening visit
Contact Sarah Medina, MD (Clinical Research Coordinator) for more information.
Phone: (212) 844-6446
Email: HBV - Clevudine vs. Adefovir in Patients with Chronic Hepatitis B who have Never Been Treated
HCV Naive, comparing Peg-Intron plus Rebetol vs. Pegasys plus Copegus
Trial Description: A head to head blinded trial comparing the efficacy and safety of three primary treatment regimens for genotype 1 hepatitis C.
Comparison of PEG-Intron® 1.5 µg/kg/wk plus Rebetol® vs PEG-Intron® 1µg/kg/wk plus Rebetol® vs Pegasys® 180 µg/wk plus Copegus (tm) in previously untreated adult subjects with chronic hepatitis C infect with genotype 1.
Doctor: George Wu, M.D., Ph.D
Contact Jay Siddiqui, M.D. or Dimple Raina for more information.
Phone: (860) 679-4260
Hep C/HIV (Great Neck, NY): Combination PegIFN in Coinfected Patients
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
Peg-Interferon Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated with Interferon
INCLUSION CRITERIA: Adult patients with Hepatitis C conifected with HIV.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis B (Farmington, CT): Entecavir Vs. Adefovir Dipivoxil
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME: Comparison of the Efficacy and Safety of Entecavir vs. Adefovir in Chronically Infected HBV Patients with Hepatic Decompensation
SUMMARY: This is an open-label study for people with chronic hepatitis B who are resistant to lamivudine and who have decompensated liver disease. This trial involves the use of an experimental new agent called entecavir vs. Adefovir.
WHO IS ELIGIBLE? Patients with decompensated chronic hepatitis B with a CTP score > 7, and evidence of lamivudine resistance (unresponsive, relapse, or breakthrough).
SPONSOR: Bristol Myers Squibb, Inc.
Contact Michelle Kelley, APRN for more information.
Phone: 860-976-8156
Hepatitis B (Great Neck, NY): Lamivudine and New Product
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
An Investigational Study Comparing a Product in Development with Lamivudine in Subjects Chronically Infected with the Hepatitis B Virus
INCLUSION CRITERIAl Adult with elevated ALT (liver enzymes), have a history of Chronic Hepatitis B (positive HbsAg), be HIV negative and not have other serious medical conditions.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis B (Valhalla, NY): Entecavir Vs. Adefovir Dipivoxil
New York Medical College
Valhalla, NY 10595
Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subject Chronically Infected with Hepatitis B Virus and Evidence of Hepatic Decompensation
INCLUSION CRITERIA: Chronic Hepatitis B with evidence of decompensation.
PRINCIPAL INVESTIGATOR: Edward Lebovics, MD
Contact Ana Casellas, RN & Carol McEwan, LPN for more information.
Phone: 914-594-3439 (914-594-3442)
Hepatitis B in Black/African-Americans and Hispanic Patients
Beth Israel Medical Center - (Directions)
10 Union Square East
New York, NY 10003
Principal Investigator: Albert Min, MD
Time frame of study: July 2007 – January 2009
Time frame of participation: Up to 76 weeks
Number of participants needed: Open
Summary:
The Division of Digestive Diseases is conducting a clinical study to test an investigational medicine for treatment of chronic hepatitis B infection in Black/African-American and Hispanic patients who never been treated for their hepatitis B infection
Criteria for Participation:
• Patients must be at least 18 years of age
• Not be co-infected with hepatitis C, hepatitis D or HIV
• Have never been treated with medication for hepatitis B
• Be willing to participate in the study, which may last up to 76 weeks
• Not be pregnant or breast-feeding
Contact Sarah Medina, MD (Clinical Research Coordinator) for more information.
Phone: (212) 844-6446
Email: Hepatitis B in Black/African-Americans and Hispanic Patients
Hepatitis C (Farmington, CT): Copegus in Non-Responders
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME: A Randomized, Open-Label, Multicenter, Efficacy and Safety Study Examining the Effects of Duration of Treatment and of a High Induction Dose of Pegasys® in Combination with Daily Copegus® in Patients with Chronic Hepatitis C who did not Respond to Previous Peginterferon Alfa-2b/Ribavirin Combination Therapy
SUMMARY: REPEAT Trial for Chronic Hepatitis C: Patients with chronic hepatitis C who have failed to respond to the combination of Peg-Intron plus Rebetol, given for at least 12 weeks may qualify for a new Trial of Pegasys® plus Copegus® therapy.
Who is eligible? Patients with chronic hepatitis C who failed at least 12 weeks of Peg-Intron Rebetol. All costs of the study and the study drugs will be paid for by the sponsor.
SPONSOR: Hoffmannn-LaRoche, Inc.
Contact Elizabeth Laska, RN for more information.
Phone: 860-679-8063 (860-825-3962)
Hepatitis C (Farmington, CT): Infergen Actimune in Non-responders
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME: Phase 2a, randomized, dose-ranging, open-label study of the safety & tolerability of consensus IFN-a Infergen IFN gamma-1b Actimune with or without RBV in the treatment of pts with CHC who are non-responders to PEG-IFN-a (2a or 2b) plus RBV
SUMMARY: To evaluate the safety and tolerability of two different doses
of IFN-γ 1b and of CIFN with or without RBV in patients with chronic hepatitis C who are non-responders to PEGIFN-α 2a (Pegasys®) or PEG-IFN-α 2b (PEG-Intron®).
WHO WILL BE ELIGIBLE? Non-cirrhotic patients with chronic hepatitis C who have failed treatment with PEG-IFN-a (2a or 2b) plus RBV. All costs covered by study.
Contact Elizabeth Laska, RN & Michelle Kelley for more information.
Phone: 860-679-4725 (860-679-8156)
Hepatitis C (Farmington, CT): Role of Iron HFE Mutations
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME: The Role of Iron HFE Mutations, and Polymorphisms of Other Genes in Chronic Hepatitis C
SUMMARY: Normal volunteers or patients with a history of chronic hepatitis C are invited to take part in a study designated to help us understand better the factors that cause progression of Hepatitis C and the response to interferon treatment of hepatitis C. The study will involve one visit to the Clinical Research Center, which will involve drawing approximately 2 tablespoons or 1 ounce of blood.
Who will be eligible? Normal volunteers and patients with chronic hepatitis C. No Co-infection with HIV or Hepatitis B, no illicit drug use in last 2 years. Subjects receive $50.
SPONSORl The NIH, NIDDK
Contact Paula Gendreau, RN for more information.
Phone: 860-679-8074
Hepatitis C (Farmington, CT): Viramidine and Ribavirin
University of Connecticut Health Center
Farmington, CT 06030
TRIAL NAME: A Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C.
SUMMARY: Dr. Aziz at the University of Connecticut and the sponsor, Valeant Pharmaceuticals, are conducting this study to determine if the drug, Viramidine, is safe and effective when compared to Ribavirin (a drug similar to Viramidine) for the treatment of hepatitis C. Ribavirin has been approved by the FDA as treatment for hepatitis C when given in combination with Pegasys„¥ (pegylated interferon). Viramidine is a pro-drug, which is preferably taken up by the liver and converted into Ribavirin. Viramidine therapy has shown to achieve 3-fold higher liver concentration of Ribavirin while serum Ribavirin levels were 50% when compared with the equivalent doses of Ribavirin. Thus Viramidine may reduce the incidence of side effects of Ribavirin because of lower blood level and possibly increase the response rate because of higher liver concentration.
Who is eligible? Patients with chronic hepatitis C who have never been treated with compensated liver disease.
SPONSOR: Valeant Pharmaceuticals
Contact Michelle Kelley, APRN for more information.
Phone: 860-679-8156
Hepatitis C (Great Neck, NY): Cirrhosis in Non-Responders
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
Patients with Cirrhosis Due to Chronic Hepatitis C Who Are Non-Responsive to Prior Interferon Alfa Treatment
INCLUSION CRITERIA: Adult Patients with serum HCV RNA positive after at least 12 weeks of interferon or combination ribavirin/interferon.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Great Neck, NY): Combination PegIFN Comparison in Genotype 1
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
Comparison of 2 Doses of Peg-Intron Plus Rebetol vs. Pegasys plus Copegus in Previously Untreated Adult Subjects with Chronic Hepatitis C Infection with Genotype 1
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Great Neck, NY): Interferon Alfacon Combination in Non-Responders
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
Phase III Study Investigating the Efficacy and Safety of Interferon Alfacon-1 Plus Ribavirin in Chronic Hepatitis C Patients Who Have Not Responded to Standard Interferon Plus Ribavirin or Pegylated Interferon Plus Ribavirin
INCLUSION CRITERIA: Adult patients with Hepatitis C who have not responded to standard interferon plus ribavirin or pegylated interferon plus ribavirin.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Great Neck, NY): Pegasys and Copegus for Genotype 2 and 3
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
Phase IV Study Evaluating the Efficacy and Safety of 16-Week vs 24-Week Treatment with Pegasys Plus Copegus in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection
INCLUSION CRITERIA: Adult patients with Chronic Hepatitis C genotype 2 or 3 infection.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Great Neck, NY): Pegasys and Ribavirin for Non-Responders
North Shore University Hospital
Manhasset, NY 11030
Safety and Efficacy Study of Pegasys Plus Ribavirin in Patients with Chronic HCV Infection Who Are Unable to Tolerate or Who Do Not Respond to 12 Weeks of PEG-Intron Plus Ribavirin
INCLUSION CRITERIA: Adult patients with Chronic Hepatitis C, have started taking PEG-Intron and ribavirin no more than 12 weeks ago, and are currently taking these drugs.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Great Neck, NY): Viramidine and Ribavirin
North Shore University Hospital - (Directions)
300 Community Drive
Manhasset, NY 11030
An Investigational Study Comparing the Safety and Efficacy of Viramidine to Ribavirin in Patients with Chronic Hepatitis C
INCLUSION CRITERIA: Chronic Hepatitis C >18 years old.
PRINCIPAL INVESTIGATOR: David Bernstein, MD
Contact Maly Tiev, RN, CCRC for more information.
Phone: 516-562-1364
Hepatitis C (Long Island, NY): Viramidine and Ribavirin in Previously Untreated Patients
Long Island, NY
Long Island, NY
TITLE: Randomized, double-blind, multicenter study to compare the safety and efficacy of viramidine to ribavirin in treatment naïve patients with chronic hepatitis C.
ELIGIBILITY:
Patients must have chronic hepatitis C
Patients must be over the age of 18
Patients must not not have received treatment for hepatitis C
Patients must be HIV negative
BACKGROUND AND PURPOSE OF THE STUDY: You are being asked to participate in a research study to evaluate an investigational drug called viramidine. An investigational drug is one that has not yet been approved by the U.S. Food and Drug Administration (FDA). You are being asked to participate in this study because you have been diagnosed with hepatitis C, a chronic infection of the liver, and you have not received any treatments for this disease.
Dr. Melissa Palmer and the sponsor, Ribapharm Inc., are conducting this study to determine if the drug, viramidine, is safe and effective when compared to ribavirin (a drug related to viramidine) for the treatment of hepatitis C. Ribavirin has been approved by the FDA as treatment for hepatitis C when given in combination with pegylated interferon, PEG-Intron®
(one of a family of proteins produced and secreted by the body’s cells in response to viral infection and other causes). They exert a number of complex actions, the principal one being inhibiting reproduction of viruses in cells.
Approximately 900 patients will be asked to participate in this study at about 80 sites, including this one, around the world, including the U.S., Canada, Europe, Australia, Brazil and Israel.
DURATION OF STUDY PARTICIPATION: If you agree to participate in this study, your participation will last up to 72 weeks (1 1/2 years). If you have type 2 or 3 hepatitis C, you will receive study medication for 24 weeks and be asked to return for 12 outpatient clinic visits. If you have type 1, 4, 5, 6, mixed or untypeable hepatitis C, you will receive study medication for 48 weeks and have 16 clinic visits. All participants will have five more visits after completing the treatment period to be followed-up for safety.
Each clinic visit will usually last about 1 to 2 hours. Some visits may take up to 6-7 hours and have several blood draws in order to determine how long the drug(s) remain in your bloodstream.
Contact Kerry Tolp for more information.
Phone: (516) 939-2626
Hepatitis C (New York, NY): IDEAL Combination PEG-Intron/Pegasys Therapy in Untreated HCV Genotype 1
New York Weill Cornell Medical Center
New York, NY
Protocol Title: Comparison of PEG-Intron 1.5 mcg/kg/wk Plus REBETOL vs PEG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 (COPEGUS)
The trial is taking place at the Center for the Study of Hepatitis C, which is a cooperative endeavor of the Rockefeller University, Weill Medical College of Cornell University and New York Presbyterian Hospital. Below are the studies that we would like to have listed.
Protocol ID: IDEAL
Type of Study: This is a Phase 3B, randomized, parallel group, double-blinded (to PEG-Intron dose only), US multicenter study
Rationale: The combination of PEG-Intron 1mcg/kg plus weight based REBETOL (800-1400 mg/day) has not been evaluated to date. This study is designed to compare the safety and efficacy of the PEG-Intron 1.5 mcg/kg combination relative to the PEG-Intron 1mcg combination. A second co-primary reason is to compare the safety and efficacy of PEG-Intron and PEGASYS.
Eligibility Criteria: Previously untreated adult subjects with chronic hepatitis infected with Genotype 1.
Treatment: Patients will be randomized into the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1:
1. PEG-Intron 1.5 mcg/kg/wk in combination with weight based REBETOL (800-1400 mg/day);
2. PEG-Intron 1 mcg/kg/wk in combination with weight based REBETOL (800-1400 mg/day)
3. PEGASYS 180 mg plus COPEGUS 1000-1200 mg/day.
Principal Investigator: Ira Jacobson, MD. New York Weill Cornell Medical Center, Division of Gastroenterology and Hepatology, 450 East 69th Street, New York, NY 10021
Contact Mary Ahern, Nurse Practitioner for more information.
Phone: 212-746-2115
Hepatitis C (New York, NY): Treatment in Naive Patients
Concorde Medical Group
New York, NY
Do you have Hepatitis C for which you have not received treatment? If so, you may be eligible to participate in a research study that provides free medication to study patients.
TO BE ELIGIBLE YOU MUST:
- Be 18 years or older
- Have Hepatitis C
- Never have received treatment for Hepatitis C
Contact Leena Hong for more information.
Phone: 212-889-5544, ext 102
Hepatitis C (Plainview, NY): Viramidine
Plainview, NY - (Directions)
1097 Old Country Road, Suite 104
Plainview, NY
Phase III Clinical Trial of Viramidine for Chronic Hepatitis C
INCLUSION CRITERIA: Chronic Hepatitis C >18 years old
PRINCIPAL INVESTIGATOR: Melissa Palmer, MD
Contact Kerry Tolp for more information.
Phone: 516-939-2626
Hepatitis C (Valhalla, NY): Peg-Intron and Ribavirin Dosing
New York Medical College
Valhalla, NY 10595
A Comparison of the Safety and Efficacy of 2 Doses of Peg Intron (1.5mcg vs. 3.0mcg) with Ribavirin (Rebetol) for Treatment of Chronic Hepatitis C Patients
Inclusion Criteria: All patients except naive patients with genotype 2 and 3
Principal Investigator: Edward Lebovics, MD
Contact Ana Casellas, RN & Carol McEwan, LPN for more information.
Phone: 914-594-3439 (914-594-3442)
Hepatitis C (Valhalla, NY): Peg-Intron and Ribavirin in Non-Responders
New York Medical College
Valhalla, NY 10595
Dose Comparison Study of Peg Intron alfa-2b and Ribavirin for Patients with Chronic Hepatitis C Who Have Not Responded to Standard Interferon and Ribavirin (1.5mcg vs. 3.0mcg)
Contact Ana Casellas, RN & Carol McEwan, LPN for more information.
Phone: 914-594-3439 ((914) 594-3442)
Hepatitis C (Valhalla, NY): PegIFN and Ribavirin for Normal ALT Level Patients
New York Medical College
Valhalla, NY 10595
Inclusion Criteria: Adult patients with Chronic Hepatitis C, compensated liver disease and 3 ALT levels within normal range at least one month apart
Principal Investigator: Edward Lebovics, MD
Contact Ana Casellas, RN & Carol McEwan, LPN for more information.
Phone: 914-594-3439 (914-594-3442)
Liver Disease (New York, NY): Pruritis
Columbia University
New York, NY
Gabapentin for the Treatment of Itching Secondary to Chronic Liver Disease of Any Cause
Inclusion Criteria: Patients from ages 18-80 with chronic pruritus secondary to liver disease, patients must have compensated liver disease, creatinine not higher than 1.7 mg/dl and hemoglobin not lower than 10 g/dl.
Principal Investigator: Nora V. Bergasa, MD
Contact Nora V. Bergasa, MD for more information.
Phone: 212-305-1021
Liver Tumor (Valhalla, NY): Acetic Acid
New York Medical College
Valhalla, NY 10595
Percutaneous Treatment of Liver Tumors with Acetic Acid
Inclusion Criteria: Presence of a primary or metastatic neoplasm in the liver. Patient considered to have surgically unresectable hepatic disease. Patient failed conventional chemotherapy or is intolerant to such therapy or no such therapy is available or chemotherapy is contraindicated die to associated medical co-morbidity.
Principal Investigators: Grigory Rozenblit, MD, David Wolf, MD
Contact Jody Hirsch, RPA-C for more information.
Phone: 914-594-3448
PBC- Investigational Medication in Combination with Ursodeoxycholic Acid (URSO, UDCA) in Patients with Primary Biliary Cirrhosis
Beth Israel Medical Center - (Directions)
Phillips Ambulatory Care Center
10 Union Square East
New York, NY 10003
Principal Investigator: Henry C. Bodenheimer, Jr., MD
Time frame of study: October 2007 – December 2008
Time frame of participation: Up to 14 weeks (99 days)
Number of participants needed: Open
Summary:
The Division of Digestive Diseases is currently looking to enroll individuals who are interested in participating in a clinical study to select an optimal dose of an investigational medication, INT-747 (a modified human bile acid), by comparing the effectiveness and safety of 3 INT-747 dose levels to 1 placebo dose level, administered to patients with primary biliary cirrhosis who continue to take ursodeoxycholic acid (URSO, UDCA)
Criteria for Participation:
Patients must be:
• At least 18 to 70 years of age
• On a stable dose of ursodeoxycholic acid (URSO, UDCA) for at least 6 months
• History of elevated alkaline phosphatase (AP) blood levels for at least 6 months
• Not pregnant or breast-feeding
• Not have other liver diseases
• Able to meet other criteria that will be discussed at a screening visit
Contact Sarah Medina, MD (Clinical Research Coordinator) for more information.
Phone: (212) 844-6446
Email: PBC- Investigational Medication in Combination with Ursodeoxycholic Acid (URSO, UDCA) in Patients with Primary Biliary Cirrhosis
Study of Exjade, the First Orally-Active Iron Binder for Hereditary Iron Overload
Who is Eligible: Persons with HFE (C282+/+)-linked hereditary hemochromatosis and with serum ferritin levels 300-1,500 ng/mL. They may not have active internal malignancies or advanced, decompensated heart, kidney, liver, or lung disease.
Trial Description: Iron overload due to a single mutation, called C282Y, of the HFE gene is the most common genetic disorder among Caucasians whose ancestors came from northern Europe. It causes the disease called HFE-linked hereditary hemochromatosis, which occurs in about 4/1,000 Caucasians. It may lead to cirrhosis of the liver, liver cancer, diabetes mellitus, and severe arthritis. These potential complications can be prevented by early diagnosis and treatment, which until now has required frequent removal of pints of blood.
Recently, an iron binder called Exjade, which can be taken by mouth, has been found to be safe and effective at removing excess iron from the body. It is an approved drug for iron overload states due to anemias and transfusions, in which removal of blood cannot be done, due to low red blood cell levels.
Within the next few months, The Liver Center and Clinical and Translational Research Center at UConn will become one of 5 study sites in the U.S.A. where Exjade will undergo initial testing for safety and tolerability for removing iron from persons with HFE (C282Y)-linked hereditary hemochromatosis.
Doctor: Herbert Bonkovsky, M.D.
Sponsor: Novartis Pharmaceuticals, the maker of Exjade
Contact Michelle Kelley, N.P. for more information.
Phone: (860) 679-8156
Email: Study of Exjade, the First Orally-Active Iron Binder for Hereditary Iron Overload
Print
del.icio.us